Yubo International Biotech annual free cash flow
2020
2021
2022
Yubo International Biotech Free Cash Flow (FCF) History (YBGJ)
Yubo International Biotech reported −$600,953 in free cash flow for fiscal 2022, an increase of $984,626 from the previous fiscal year, with a free cash flow margin of −576.27%.
View full Yubo International Biotech company overviewYubo International Biotech free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2022 | 2022-12-31 | −$600,953 | $984,626 | — | −576.27% |
| 2021 | 2021-12-31 | −$1.6M | −$1.6M | — | −127.42% |
| 2020 · Dec 31 | 2020-12-31 | $58,551 | — | — | — |
Yubo International Biotech quarterly free cash flow
Q1.20
Q1.21
Q2.21
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q1.24
Q1.25
Q1.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | −$207,157 | −$54,132 | — | — |
| Q1 2025 | 2025-03-31 | −$398,229 | −$365,560 | — | — |
| Q1 2024 | 2024-03-31 | −$349,526 | $340,005 | — | −10020.81% |
| Q3 2023 | 2023-09-30 | $5,076 | −$50,160 | −90.81% | +1.18% |
| Q2 2023 | 2023-06-30 | −$153,025 | −$125,786 | — | −10701.05% |
| Q1 2023 | 2023-03-31 | −$32,669 | −$74,028 | — | −20.86% |
| Q4 2022 | 2022-12-31 | −$689,531 | −$607,808 | — | −1036.58% |
| Q3 2022 | 2022-09-30 | $55,236 | $126,270 | — | +378.85% |
| Q2 2022 | 2022-06-30 | −$27,239 | $31,866 | — | −341.77% |
| Q1 2022 | 2022-03-31 | $41,359 | $1.5M | — | +271.87% |
| Q4 2021 | 2021-12-31 | −$81,723 | $54,623 | — | — |
| Q3 2021 · Sep 30 | 2021-09-30 | −$71,034 | −$271,793 | — | −72.26% |
| Q2 2021 · Jun 30 | 2021-06-30 | −$59,105 | $480,768 | — | — |
| Q1 2021 · Mar 31 | 2021-03-31 | −$1.5M | — | — | — |
| Q2 2021 · Sep 30 | 2020-09-30 | −$136,346 | — | — | — |
| Q1 2021 · Jun 30 | 2020-06-30 | $200,759 | — | — | — |
| Q1 2020 · Mar 31 | 2020-03-31 | −$539,873 | — | — | — |
Yubo International Biotech free cash flow growth trends
Yubo International Biotech's latest reported quarter, Q1 2026, generated −$207,157 in free cash flow, a decrease of $54,132 year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Yubo International Biotech filings at SEC.gov ↗